Peptide Schedule
Romiplostim (Nplate)14 residuesIEGPTLRQWLAARAEach bubble = one amino acid. Size = residue mass. Color = chemical class.Romiplostim (Nplate)
Benefits
About Romiplostim (Nplate)
Romiplostim (Nplate) is an FDA-approved Fc-peptide fusion protein (peptibody) that acts as a thrombopoietin receptor (c-Mpl) agonist. It stimulates megakaryopoiesis and platelet production by binding to and activating the TPO receptor, mimicking the action of endogenous thrombopoietin. Approved for the treatment of immune thrombocytopenia (ITP) in adults and pediatric patients who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Romiplostim increases platelet counts in a dose-dependent manner, typically within 1-2 weeks of initiation.
Who Should Consider Romiplostim (Nplate)
- Adults with chronic immune thrombocytopenia (ITP) with insufficient response to corticosteroids, IVIg, or splenectomy
- Pediatric patients ≥1 year with ITP lasting ≥6 months with insufficient response to prior treatment
- ITP patients seeking to reduce corticosteroid dependence
- Patients with ITP at high bleeding risk due to persistently low platelet counts
How Romiplostim (Nplate) Works
Romiplostim is an Fc-peptide fusion protein (peptibody) consisting of two identical single-chain subunits, each with a human IgG1 Fc domain linked to a peptide containing two thrombopoietin receptor (c-Mpl) binding domains. It binds to and activates the TPO receptor on megakaryocyte precursors in the bone marrow, triggering the JAK2/STAT5 and MAPK signaling cascades. This stimulates megakaryocyte proliferation, differentiation, and maturation, leading to increased platelet production. Unlike endogenous TPO, romiplostim has no amino acid sequence homology with TPO, reducing the risk of cross-reactive antibodies.
What to Expect
Initiate at 1 mcg/kg weekly; baseline CBC obtained; platelet response not yet expected
Platelet counts begin to rise; dose titrated weekly by 1 mcg/kg based on response
Majority of responders achieve target platelet count ≥50 × 10⁹/L; concurrent ITP medications may begin tapering
Stable platelet counts maintained; dose adjustments become less frequent; monitoring interval may extend to monthly
Durable long-term response; some patients may achieve sustained remission allowing dose reduction
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 1mcg | Weekly |
| Moderate | 3mcg | Weekly |
| Aggressive | 10mcg | Weekly |
Note: FDA-approved thrombopoietin receptor agonist (peptibody). Weight-based dosing: 1-10 mcg/kg SC weekly. Adjust by 1 mcg/kg increments to achieve platelet count ≥50 × 10⁹/L. Requires regular CBC monitoring. REMS program applies.
How to Inject Romiplostim (Nplate)
Reconstitute 250 mcg vial with 0.72 mL sterile water for injection (yielding 500 mcg/mL) or 500 mcg vial with 1.2 mL sterile water (yielding 500 mcg/mL). Gently swirl — do not shake. Allow to sit ~5 minutes until clear and colorless. Calculate dose based on current body weight (mcg/kg × weight = total mcg). Administer subcutaneously into the upper arm, thigh, or abdomen. Rotate injection sites. Administer once weekly on the same day. Monitor CBC with differential weekly until stable platelet count achieved, then monthly thereafter.
Cycling Protocol
Romiplostim is administered continuously as long-term maintenance therapy, not cycled. Dose is titrated weekly by 1 mcg/kg increments based on platelet counts, starting at 1 mcg/kg. Target platelet count is ≥50 × 10⁹/L. Maximum dose is 10 mcg/kg/week. Do not abruptly discontinue — rebound thrombocytopenia may occur.
Pharmacokinetics
Source: Wang B et al. Clin Pharmacokinet. 2010;49(10):655-665. Median terminal half-life ~3.5 days (range 1-34 days).
Loading the interactive decay curve.
Side Effects
Common: headache (35%), arthralgia (26%), dizziness (17%), insomnia (16%), myalgia (14%), abdominal pain (11%), shoulder pain (8%), paresthesia (6%). Serious risks: bone marrow reticulin fiber deposition (reversible on discontinuation), thromboembolic events, rebound thrombocytopenia upon cessation, and potential progression of myelodysplastic syndromes (MDS) in at-risk patients. Neutralizing antibodies to romiplostim or endogenous TPO are rare but monitored.
Contraindications
- Known hypersensitivity to romiplostim or any component of the formulation
- Myelodysplastic syndromes (MDS) or other hematologic malignancies — risk of blast progression
- Active thromboembolic disease or high thrombotic risk without anticoagulation
- Hepatic impairment with portal hypertension-related thrombocytopenia (not ITP)
- Pregnancy (Category C) — use only if potential benefit justifies risk to fetus
Drug Interactions
- Corticosteroids — romiplostim may allow dose reduction; taper gradually under monitoring
- Anticoagulants and antiplatelet agents — bleeding risk may change as platelet counts rise; adjust doses accordingly
- Azathioprine, mycophenolate, other immunosuppressants — additive ITP treatment; monitor closely during tapering
- IVIg — rescue use may be reduced; do not adjust romiplostim dose based solely on IVIg-induced platelet spikes
- Eltrombopag (Promacta) — do not combine TPO receptor agonists; overlapping mechanism with increased thrombotic risk
Storage & Stability
Molecular Profile
Related Peptides
References
- Kuter DJ et al. Efficacy of romiplostim in patients with chronic ITP (Lancet 2008)PubMed 18242413
- Bussel JB et al. Effect of eltrombopag on platelet counts in chronic ITP (Lancet 2009)PubMed 19231632
- Kuter DJ et al. Long-term treatment with romiplostim: safety and efficacy (Br J Haematol 2013)PubMed 23432359
- FDA Prescribing Information: Nplate (romiplostim)FDA Label
- Wang B et al. Clinical pharmacokinetics and pharmacodynamics of romiplostim (Clin Pharmacokinet 2010)PubMed 20818832